CompletedNCT00402324
Olanzapine added to a mood stabilizer for mixed episodes in bipolarity
About this title
Read the official source — NCT00402324Medication studyAges 18–60United States
Understand this study
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- HialeahSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 202
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00402324
- Official title
Show the full official title
A Double-Blind Placebo Controlled Trial of Divalproex and Olanzapine in Bipolar I Disorder, Mixed Episode
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Hialeah
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including olanzapine, placebo and divalproex.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
